212 related articles for article (PubMed ID: 38662144)
1. A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma.
Michaelsen GL; da Silva LDRE; de Lima DS; Jaeger MDC; Brunetto AT; Dalmolin RJS; Sinigaglia M
J Mol Neurosci; 2024 Apr; 74(2):47. PubMed ID: 38662144
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients.
Chen K; Huang B; Yan S; Xu S; Li K; Zhang K; Wang Q; Zhuang Z; Wei L; Zhang Y; Liu M; Lian H; Zhong C
Aging (Albany NY); 2020 Nov; 12(21):21481-21503. PubMed ID: 33159021
[TBL] [Abstract][Full Text] [Related]
4. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.
Banfield E; Brown AL; Peckham EC; Rednam SP; Murray J; Okcu MF; Mitchell LE; Chintagumpala MM; Lau CC; Scheurer ME; Lupo PJ
Cancer Epidemiol; 2016 Oct; 44():161-166. PubMed ID: 27607585
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of gene expression and DNA methylation through one-class logistic regression machine learning identifies stemness features in medulloblastoma.
Lian H; Han YP; Zhang YC; Zhao Y; Yan S; Li QF; Wang BC; Wang JJ; Meng W; Yang J; Wang QH; Mao WW; Ma J
Mol Oncol; 2019 Oct; 13(10):2227-2245. PubMed ID: 31385424
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
8. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
9. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
10. A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma.
Zhao X; Song T; He Z; Tang L; Zhu Y
Med Oncol; 2010 Sep; 27(3):985-91. PubMed ID: 19806481
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
[TBL] [Abstract][Full Text] [Related]
14. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA profiling of pediatric Medulloblastoma.
Kesherwani V; Shukla M; Coulter DW; Sharp JG; Joshi SS; Chaturvedi NK
BMC Med Genomics; 2020 Jun; 13(1):87. PubMed ID: 32591022
[TBL] [Abstract][Full Text] [Related]
16. CTGF expression is indicative of better survival rates in patients with medulloblastoma.
Cruzeiro GAV; Lira RCP; de Almeida Magalhães T; Scrideli CA; Valera ET; Baumgartner M; Tone LG
Cancer Gene Ther; 2020 May; 27(5):378-382. PubMed ID: 31073205
[TBL] [Abstract][Full Text] [Related]
17. Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
Korshunov A; Okonechnikov K; Stichel D; Ryzhova M; Schrimpf D; Sahm F; Sievers P; Absalyamova O; Zheludkova O; Golanov A; Jones DTW; Pfister SM; von Deimling A; Kool M
Neuro Oncol; 2021 Sep; 23(9):1576-1585. PubMed ID: 33589929
[TBL] [Abstract][Full Text] [Related]
18. Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma.
Li J; Zhao S; Lee M; Yin Y; Li J; Zhou Y; Ballester LY; Esquenazi Y; Dashwood RH; Davies PJA; Parsons DW; Li XN; Huang Y; Sun D
Sci Adv; 2020 Oct; 6(42):. PubMed ID: 33067228
[TBL] [Abstract][Full Text] [Related]
19. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Faoro D; von Bueren AO; Shalaby T; Sciuscio D; Hürlimann ML; Arnold L; Gerber NU; Haybaeck J; Mittelbronn M; Rutkowski S; Hegi M; Grotzer MA
J Neurooncol; 2011 May; 103(1):59-69. PubMed ID: 20820873
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.
Frühwald MC; O'Dorisio MS; Dai Z; Tanner SM; Balster DA; Gao X; Wright FA; Plass C
Oncogene; 2001 Aug; 20(36):5033-42. PubMed ID: 11526488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
